show (84) that the nucleosome-binding domain F3 peptide of HMGN2 is a promising potential tumor therapeutic target, suggesting unique prospects for drug-targeting applications because it can be absorbed by cells and carry payloads to the nucleus. Here, HMGN2 is linked to neoplasm.